Paradigm Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Paradigm Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-130	Closed	-$32.4K	–	410
2020 Q3	$32.4K	Hold	130	–	–	0.01%	374
2020 Q2	$45.2K	Buy	+130	New	+$40.6K	0.01%	373
2018 Q4	–	Sell	-40	Closed	-$36.6K	–	418
2018 Q3	$36.6K	Buy	40 +10	+33%	+$8.54K	0.01%	387
2018 Q2	$22K	Hold	30	–	–	0.01%	394
2018 Q1	$47.8K	Hold	30	–	–	0.01%	354
2017 Q4	$26.9K	Sell	30 -187	-86%	-$111K	0.01%	383
2017 Q3	$78K	Hold	217	–	–	0.02%	342
2017 Q2	$63.5K	Buy	217 +10	+5%	+$2.89K	0.01%	487
2017 Q1	$72.8K	Buy	+207	New	+$46.5K	0.01%	557
2016 Q3	–	Sell	-467	Closed	-$99.6K	–	738
2016 Q2	$99.6K	Sell	467 -680	-59%	-$152K	0.02%	451
2016 Q1	$237K	Hold	1,147	–	–	0.04%	294
2015 Q4	$290K	Buy	+1,147	New	+$236K	0.05%	326

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Paradigm Asset Management's NKTR Position: Q4 2020 in Review

Paradigm Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 130 shares — an estimated $32.4K sold.

Paradigm Asset Management first reported a position in NKTR in Q4 2015 and held it in 12 quarters. The position peaked at $290K in Q4 2015. 245 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

Paradigm Asset Management reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
Paradigm Asset Management sold 130 Nektar Therapeutics shares in Q4 2020, an estimated $32.4K.
Paradigm Asset Management first reported a position in Nektar Therapeutics in Q4 2015 and held it in 12 quarters.
Paradigm Asset Management's Nektar Therapeutics position peaked at $290K in Q4 2015.
245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Paradigm Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.